Ascendis Pharma A/S (NASDAQ:ASND) Receives $216.07 Average Price Target from Analysts

Shares of Ascendis Pharma A/S (NASDAQ:ASND) have received a consensus recommendation of “Buy” from the fifteen brokerages that are currently covering the company, Marketbeat Ratings reports. Fifteen research analysts have rated the stock with a buy rating. The average 12 month price objective among brokerages that have covered the stock in the last year is $216.07.

A number of brokerages have recently commented on ASND. Wedbush upped their target price on Ascendis Pharma A/S from $181.00 to $212.00 and gave the stock an “outperform” rating in a research note on Friday, May 2nd. Morgan Stanley upgraded Ascendis Pharma A/S from an “equal weight” rating to an “overweight” rating and upped their price objective for the stock from $180.00 to $250.00 in a research report on Monday, May 5th. JPMorgan Chase & Co. raised their price objective on shares of Ascendis Pharma A/S from $200.00 to $245.00 and gave the stock an “overweight” rating in a research note on Friday, May 2nd. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $200.00 price objective on shares of Ascendis Pharma A/S in a research note on Monday, May 12th. Finally, The Goldman Sachs Group raised their price objective on shares of Ascendis Pharma A/S from $200.00 to $225.00 and gave the stock a “buy” rating in a research note on Thursday, February 13th.

Institutional Trading of Ascendis Pharma A/S

Several institutional investors have recently modified their holdings of ASND. Point72 Asia Singapore Pte. Ltd. acquired a new stake in shares of Ascendis Pharma A/S in the fourth quarter valued at about $28,000. Jones Financial Companies Lllp grew its position in shares of Ascendis Pharma A/S by 394.0% in the fourth quarter. Jones Financial Companies Lllp now owns 247 shares of the biotechnology company’s stock valued at $34,000 after purchasing an additional 197 shares during the period. Brooklyn Investment Group grew its position in shares of Ascendis Pharma A/S by 332.9% in the first quarter. Brooklyn Investment Group now owns 355 shares of the biotechnology company’s stock valued at $55,000 after purchasing an additional 273 shares during the period. Blue Trust Inc. grew its position in shares of Ascendis Pharma A/S by 415.2% in the fourth quarter. Blue Trust Inc. now owns 407 shares of the biotechnology company’s stock valued at $56,000 after purchasing an additional 328 shares during the period. Finally, Quarry LP acquired a new stake in shares of Ascendis Pharma A/S in the fourth quarter valued at about $96,000.

Ascendis Pharma A/S Trading Up 0.0%

NASDAQ ASND opened at $157.60 on Wednesday. The company has a fifty day simple moving average of $157.15 and a two-hundred day simple moving average of $142.36. The stock has a market cap of $9.61 billion, a P/E ratio of -22.20 and a beta of 0.41. Ascendis Pharma A/S has a 12-month low of $111.09 and a 12-month high of $183.00.

Ascendis Pharma A/S (NASDAQ:ASND) last posted its earnings results on Thursday, May 1st. The biotechnology company reported ($1.66) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.56) by ($0.10). The company had revenue of $123.97 million for the quarter, compared to the consensus estimate of $98.56 million. As a group, sell-side analysts forecast that Ascendis Pharma A/S will post -4.34 earnings per share for the current year.

Ascendis Pharma A/S Company Profile

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.